Antiretroviral News and Research RSS Feed - Antiretroviral News and Research

CWRU researcher receives $3.9 million grant for HIV research

CWRU researcher receives $3.9 million grant for HIV research

A researcher at Case Western Reserve University School of Medicine has been awarded $3.9 million to determine if the combination of the human immunodeficiency virus (HIV) and drug abuse is a double kick in the gut, leading to organ damage throughout the body. [More]
Researchers develop smartphone accessory for rapid diagnosis of infectious diseases at point of care

Researchers develop smartphone accessory for rapid diagnosis of infectious diseases at point of care

A team of researchers, led by Samuel K. Sia, associate professor of biomedical engineering at Columbia Engineering, has developed a low-cost smartphone accessory that can perform a point-of-care test that simultaneously detects three infectious disease markers from a finger prick of blood in just 15 minutes. [More]
Research opens door to development of new therapies to block HIV-associated neurocognitive disorders

Research opens door to development of new therapies to block HIV-associated neurocognitive disorders

While antiretroviral therapies have significantly improved and extended the lives of many HIV patients, another insidious and little discussed threat looms for aging sufferers - HIV-associated neurocognitive disorders (HAND). The disorders, which strike more often in HIV patients over age 50, can result in cognitive impairment, mild to severe, making everyday tasks a challenge. [More]
Theravance Biopharma, Mylan partner to develop and commercialize TD-4208 for COPD treatment

Theravance Biopharma, Mylan partner to develop and commercialize TD-4208 for COPD treatment

Theravance Biopharma, Inc. and Mylan Inc. today announced that the two companies will partner on the development and, subject to FDA approval, commercialization of TD-4208, a novel investigational once-daily nebulized long-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease (COPD) and other respiratory diseases. [More]
Mylan signs definitive agreement to acquire Famy Care's female health care businesses

Mylan signs definitive agreement to acquire Famy Care's female health care businesses

Mylan Inc. today announced that it has, through its Indian subsidiary Mylan Laboratories Limited, signed a definitive agreement to acquire certain female health care businesses from Famy Care Limited, a specialty women's health care company with global leadership in generic oral contraceptive products (OCPs) for $750 million in cash plus additional contingent payments of up to $50 million. [More]
Researchers gain new insight on immune cells that harbor latent HIV virus

Researchers gain new insight on immune cells that harbor latent HIV virus

Drugs for HIV have become adept at suppressing infection, but they still can't eliminate it. That's because the medication in these pills doesn't touch the virus' hidden reserves, which lie dormant within infected white blood cells. Unlock the secrets of this pool of latent virus, scientists believe, and it may become possible to cure - not just control - HIV. [More]
Study shows only 15% of newly diagnosed adults seek HIV care

Study shows only 15% of newly diagnosed adults seek HIV care

Between December 2009 and February 2011, health workers with the AMPATH Consortium sought to test and counsel every adult resident in the Bunyala subcounty of Kenya for HIV. [More]
Researchers receive $2.2M grant to study links between depression and cardiovascular disease in HIV patients

Researchers receive $2.2M grant to study links between depression and cardiovascular disease in HIV patients

Jesse Stewart, Ph.D., associate professor of psychology in the School of Science at Indiana University-Purdue University Indianapolis, and two colleagues have received a $2.2 million National Institutes of Health grant to investigate the links between depression, depression treatment and cardiovascular disease in adults with HIV. [More]
Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson today announced sales of $18.3 billion for the fourth quarter of 2014, a decrease of 0.6% as compared to the fourth quarter of 2013. Operational results increased 3.9% and the negative impact of currency was 4.5%. Domestic sales increased 7.4%. [More]
AbbVie gets European Commission's approval to market VIEKIRAX + EXVIERA for HCV treatment

AbbVie gets European Commission's approval to market VIEKIRAX + EXVIERA for HCV treatment

AbbVie announced that the European Commission has granted marketing authorizations for its all-oral, short-course, interferon-free treatment of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets). The treatment has been approved with or without ribavirin (RBV) for patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients. [More]
Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen R&D Ireland announced today an amendment to its existing agreement with Gilead Sciences, Inc., initially established in 2011, for the development of a once daily, darunavir-based, single-tablet regimen (STR) for the treatment of people living with HIV. [More]
FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

The U.S. Food and Drug Administration has approved AbbVie's VIEKIRA PAK, an all-oral, interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection, including those with compensated cirrhosis. [More]
Heroin use impacts HIV disease progression

Heroin use impacts HIV disease progression

Researchers at Yale and Boston University and their Russian collaborators have found that occasional heroin use by HIV-positive patients may be particularly harmful to the immune system and worsens HIV disease, compared to persistent or no heroin use. [More]
Mylan announces U.S. launch of Prednisolone Sodium Phosphate Orally Disintegrating Tablets

Mylan announces U.S. launch of Prednisolone Sodium Phosphate Orally Disintegrating Tablets

Mylan Inc. today announced the U.S. launch of its Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg, 15 mg, and 30 mg. This product is the first generic version of Shionogi's Orapred ODT. [More]

Mylan introduces Methocarbamol Injection USP, 100 mg/mL in the U.S.

Mylan Inc. today announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product is the generic version of Hikma Maple Ltd.'s Robaxin. [More]
Mylan announces U.S. launch of Celecoxib Capsules

Mylan announces U.S. launch of Celecoxib Capsules

Mylan Inc. today announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first available generic versions of Pfizer's Celebrex Capsules, which is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults. [More]
Verizon announces winners of 2014 Powerful Answers Award

Verizon announces winners of 2014 Powerful Answers Award

The wait is over. Verizon is proud to announce the winners of Verizon's 2014 Powerful Answers Award, three in each of the following categories: education, health care, sustainability and transportation. [More]
New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

New treatment combinations and targeted therapies for lymphoma and multiple myeloma are improving outcomes for vulnerable patient populations with hard-to-treat disease, according to studies presented today at the 56th American Society of Hematology Annual Meeting and Exposition. [More]
Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration for its New Drug Applications (NDAs) for two dosages of abacavir/lamivudine tablets for oral suspension for the treatment of HIV-1 infection in pediatric patients. [More]
UCLA researchers devise plan to reduce HIV transmission in Africa

UCLA researchers devise plan to reduce HIV transmission in Africa

While Ebola has attracted much of the world's attention recently, a severe HIV epidemic rages on around the world and in sub-Saharan Africa in particular. Globally, more than 34 million people are infected with HIV; in sub-Saharan Africa alone, 3 million new infections occur annually. [More]
Advertisement
Advertisement